Certain substances besides benzodiazepines may trigger a positive result on a urine drug screening intended to detect benzodiazepine use. These false positives can occur due to cross-reactivity with structurally similar compounds or metabolites. For instance, some non-steroidal anti-inflammatory drugs (NSAIDs), specifically naproxen, have been implicated in generating false positive results. Furthermore, sertraline, an antidepressant, and certain other medications might, in rare instances, lead to similar outcomes. It is important to understand that the exact mechanism for these false positives varies depending on the specific drug screening assay used and the individual’s metabolic processes.
Accurate interpretation of urine drug screens is vital for clinical decision-making, employment screening, and legal proceedings. Erroneous positive results can have significant ramifications, impacting individuals’ medical care, employment status, and legal standing. Historically, reliance on initial screening tests without confirmatory testing has led to misinterpretations and unjust consequences. Therefore, awareness of potential interfering substances and the implementation of confirmatory testing, such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), are essential safeguards.